Vasculitis
1 month ago
@abdelhamed012 @RheumNow Same https://t.co/uScez6UwBp
1 month ago
🤵‍♂️Results from BACHELOR
➡️34 PMR pts
➡️18 BARI, 16 PBO
➡️Primary endpoint: CRP PMR-AS≤10 w/o oral GC rescue from W0 to 12
78% BARI pts reached primary endpoint vs 13% PBO
No new safety signals
BARI 4mg 12W, then 2mg 12W➡️36W low disease activity in PMR
Ab0858 #ACR24 @RheumNow
1 month ago
Systematic review suggests (although not provn) that audiovestibular dysfunction may be from APS. Anti-phospholipid & HSP-70 Abs found 25-33% w/idiopathic sudden sensorineural hearing loss,. ACL Abs seen in up to 27% w/ sensorineural hearing loss https://t.co/WcmeCP0ryq https://t.co/DiYX57R0uG
1 month ago
Harkins @DrTrishHarkins et al. 1 year outcomes of 65 PMR patients treated in FTC. 32.7% experienced relapse, 28% still on GCs, 21% on tocilizumab. @RheumNow #ACR24 Abstr#0739 https://t.co/uYBYhPqGQE https://t.co/n9x9BDTPKg
1 month ago
Results from MANDARA- #EGPA pts treated with benralizumab or mepolizumab
Eosinophil-targeting biologics rapidly control airway- & non-airway-related manifestations
Few pts had worsening of disease that progressed to organ damage over 52W
Ab0828 #ACR24 @RheumNow https://t.co/hIn9iyNVWQ
Clinicians treating giant cell arteritis (GCA) have long had to contend with a disappointingly limited selection of drugs from which to select. Glucocorticoids were until relatively recently our sole…
1 month ago
Langford et al. Abatacept NOT effective in GPA in ABROGATE RCT. 65 patients. Relapse/worsening in 62% vs 68%. No difference in any secondary end-point. @RheumNow #ACR24 Abstr#0823 https://t.co/yRFZ2diJFF https://t.co/LgXkPnDArE
1 month ago
This abstract reports that patients with ESRD 2/2 to GPA have a higher risk of vertebral fractures compared to individuals with ESRD without GPA. Even low dose steroids (pred 5mg) taken during the first year of HD conferred an increase risk or facture! #ACR24 @RheumNow https://t.co/4xM3XTCHSH
1 month ago
Harkins @DrTrishHarkins et al. People with PMR exhibit an accelerated physical aging phenotype at baseline. High rates of frailty (41%), pre-frailty (28%), cognitive impairment (74%!), sarcopenia (23%), osteoporosis (21%) @RheumNow #ACR24 Abstr#0740 https://t.co/4ZT8VtGi1W https://t.co/xBQ5CLlb5A